Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC).

被引：0
|
作者：
Goh, Jeffrey [1 ]
Coward, Jermaine [1 ]
Gao, Bo [2 ]
da Silva, Ines P. [3 ,4 ]
Voskoboynik, Mark [5 ,6 ]
Day, Daphne [7 ,8 ]
Body, Amy L. [7 ,8 ]
Gan, Hui K. [9 ]
Chen, Cheng [10 ]
Xiang, Xiao [10 ]
Fei, Cong [10 ]
Yang, Liu [10 ]
Millward, Michael [11 ,12 ]
机构：
[1] Icon Canc Ctr, Brisbane, Qld, Australia
[2] Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[3] Blacktown Hosp, Sydney, NSW, Australia
[4] Westmead Hosp, Sydney, NSW, Australia
[5] Nucleus Network, Melbourne, Vic, Australia
[6] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia
[7] Monash Hlth, Melbourne, Vic, Australia
[8] Monash Univ, Melbourne, Vic, Australia
[9] Austin Hlth, Heidelberg, Vic, Australia
[10] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[11] Linear Clin Res, Nedlands, WA, Australia
[12] Univ Western Australia, Nedlands, WA, Australia
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT013
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical and pharmacodynamic activity of decitabine in vivo for patients with recurrent, platinum-resistant, epithelial ovarian cancer
    Fang, Fang
    Balch, Curt
    Schilder, Jeanne
    Zhang, Shu
    Shen, Changyu
    Li, Lang
    Snyder, Anthony
    Nephew, Kenneth
    Matei, Daniela
    [J]. CANCER RESEARCH, 2009, 69
  • [42] Efficacy and safety of apatinib in the treatment of advanced platinum-resistant recurrent epithelial ovarian cancer: A retrospective study.
    Pan, Zhongmian
    Luo, Zhongbin
    He, Hongying
    Chen, Yujie
    Zhao, Bingbing
    Yang, Zhijun
    Li, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17594 - E17594
  • [43] Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
    Khan, N.
    Newman, J.
    Rahman, H.
    Lee, C-S.
    Kohn, N.
    Seetharamu, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S373 - S374
  • [44] Mirvetuximab Soravtansine Improves OS in Patients With Platinum-Resistant Ovarian Cancer
    Coleman, Robert L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 363 - 364
  • [45] Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
    Gao, Bo
    Zhao, Jun
    Huang, Dingzhi
    Sun, Meili
    Ma, Zhiyong
    Chu, Qian
    Liu, Yunpeng
    Wang, Zhehai
    Li, Xin
    Li, Hui
    Zhang, Juan
    Sun, Jingchao
    Peng, Yanyan
    Wu, Yi-Long
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 124 - 124
  • [46] Homologous recombination deficiency and platinum rechallenge in platinum-resistant ovarian cancer patients.
    Da Costa, Alexandre Andre B. A.
    Salvadori, Marcela Marinelli
    Valadares, Camila Vieira
    Stecca, Carlos
    Brot, Louise
    do Canto, Luisa Matos
    Baiocchi, Glauco
    Rogatto, Silvia Regina
    Achatz, Maria Isabel Waddington
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer
    Nasu, Hiroki
    Nishio, Shin
    Park, Jongmyung
    Yoshimitsu, Teruyuki
    Matsukuma, Ken
    Tasaki, Kazuto
    Katsuda, Takahiro
    Terada, Atsumu
    Tsuda, Naotake
    Ushijima, Kimio
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (04) : 790 - 801
  • [48] External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer
    Oufkir, Nina
    Rouzier, Roman
    Paoletti, Xavier
    Bonneau, Claire
    [J]. JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [49] Does early treatment with platinum improve survival in patients with platinum-resistant ovarian cancer?
    Stany, M. P.
    Bidus, M. A.
    Dainty, L. A.
    Krivak, T. C.
    McHale, M. T.
    Winter, W. E.
    Tedjarati, S. S.
    Bieber, A.
    Berek, J. S.
    Rose, G. S.
    Elkas, J. C.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S125 - S126
  • [50] Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S630 - S631
12345